Spero Therapeutics has licensed rights to an anti-CD40L antibody developed by China's Innovent Biologics, planning to develop ...

After a delay, Eisai and Biogen have won FDA approval for their new subcutaneous formulation of Alzheimer's disease therapy ...

New biotech Avere Therapeutics has taken a fast-track to becoming a publicly listed company by merging with NextCure, with a ...

A study has shown that, for people living with advanced cancer, a simple, weekly remote check-in with their care team can ...

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5 billion agreement that gives it global rights ...

The University of Oxford has launched what it says is the world's first phase I clinical trial of a vaccine specifically ...

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...

As the hype builds around radiopharmaceuticals, Novartis’s Pluvicto (lutetium PSA) remains one of the few that’s actually made it to market. In a conversation at ASCO 2026, Dr Fred Saad of the ...

Hundreds of researchers at the Institute of Cancer Research (ICR) in London have held historic strikes across sites in Sutton ...

Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for ...

Organisations are beginning to rethink field integration more holistically out of a realisation that consistency in ...